CA2512798A1 - Fluorescence based t-type channel assay - Google Patents
Fluorescence based t-type channel assay Download PDFInfo
- Publication number
- CA2512798A1 CA2512798A1 CA002512798A CA2512798A CA2512798A1 CA 2512798 A1 CA2512798 A1 CA 2512798A1 CA 002512798 A CA002512798 A CA 002512798A CA 2512798 A CA2512798 A CA 2512798A CA 2512798 A1 CA2512798 A1 CA 2512798A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- channel
- calcium ion
- type
- channels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003691 T-Type Calcium Channels Human genes 0.000 title claims abstract description 49
- 108090000030 T-Type Calcium Channels Proteins 0.000 title claims abstract description 49
- 238000003556 assay Methods 0.000 title abstract description 22
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 43
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims description 66
- 239000012528 membrane Substances 0.000 claims description 43
- 108091006146 Channels Proteins 0.000 claims description 32
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 26
- 229910001424 calcium ion Inorganic materials 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 229910001414 potassium ion Inorganic materials 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 18
- 108010026389 Gramicidin Proteins 0.000 claims description 17
- 229960004905 gramicidin Drugs 0.000 claims description 17
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical group C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 16
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 13
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 11
- 108010057232 inward rectifier potassium channel 2 Proteins 0.000 claims description 8
- 229910001415 sodium ion Inorganic materials 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 108090000862 Ion Channels Proteins 0.000 claims description 6
- 102000004310 Ion Channels Human genes 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 102000004257 Potassium Channel Human genes 0.000 claims description 4
- -1 TASK-1 Proteins 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 108020001213 potassium channel Proteins 0.000 claims description 4
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 101001050878 Homo sapiens Potassium channel subfamily K member 9 Proteins 0.000 claims description 3
- 102100023204 Potassium channel subfamily K member 2 Human genes 0.000 claims description 3
- 102100023205 Potassium channel subfamily K member 4 Human genes 0.000 claims description 3
- 101710185483 Potassium channel subfamily K member 4 Proteins 0.000 claims description 3
- 102100024986 Potassium channel subfamily K member 9 Human genes 0.000 claims description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 108010083945 potassium channel protein TREK-1 Proteins 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 2
- 101000974745 Homo sapiens Potassium channel subfamily K member 10 Proteins 0.000 claims description 2
- 101710124951 Phospholipase C Proteins 0.000 claims description 2
- 102100022798 Potassium channel subfamily K member 10 Human genes 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 abstract description 2
- 201000000980 schizophrenia Diseases 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000013537 high throughput screening Methods 0.000 abstract 1
- 208000000509 infertility Diseases 0.000 abstract 1
- 230000036512 infertility Effects 0.000 abstract 1
- 231100000535 infertility Toxicity 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 239000011575 calcium Substances 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 4
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 4
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000009460 calcium influx Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 238000012203 high throughput assay Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000036390 resting membrane potential Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 208000034321 Familial paroxysmal ataxia Diseases 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000000060 Migraine with aura Diseases 0.000 description 2
- 108010075750 P-Type Calcium Channels Proteins 0.000 description 2
- 208000003554 absence epilepsy Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000004139 episodic ataxia type 2 Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- 241000238898 Agelenopsis aperta Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000017055 Dipluridae Species 0.000 description 1
- 102000016675 EF-hand domains Human genes 0.000 description 1
- 108050006297 EF-hand domains Proteins 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700012358 P/Q-type calcium channel Proteins 0.000 description 1
- 102000050761 P/Q-type calcium channel Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010027023 Q-Type Calcium Channels Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229940126495 T-type calcium channel blocker Drugs 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 108091092197 high voltage-gated calcium channel activity Proteins 0.000 description 1
- 102000040854 high voltage-gated calcium channel activity Human genes 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 102000038652 low voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091092917 low voltage-gated calcium channel activity Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43861603P | 2003-01-07 | 2003-01-07 | |
| US60/438,616 | 2003-01-07 | ||
| US45740503P | 2003-03-24 | 2003-03-24 | |
| US60/457,405 | 2003-03-24 | ||
| PCT/CA2004/000023 WO2004060917A2 (en) | 2003-01-07 | 2004-01-07 | Fluorescence based t-type channel assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2512798A1 true CA2512798A1 (en) | 2004-07-22 |
Family
ID=32717990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002512798A Abandoned CA2512798A1 (en) | 2003-01-07 | 2004-01-07 | Fluorescence based t-type channel assay |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7270949B2 (enExample) |
| EP (1) | EP1581558A2 (enExample) |
| JP (1) | JP2006526389A (enExample) |
| CA (1) | CA2512798A1 (enExample) |
| WO (1) | WO2004060917A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259866A1 (en) * | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
| WO2006105670A1 (en) * | 2005-04-08 | 2006-10-12 | Neuromed Pharmaceuticals Ltd. | Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
| WO2007133481A2 (en) * | 2006-05-11 | 2007-11-22 | Neuromed Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| KR100958291B1 (ko) | 2008-01-23 | 2010-05-19 | 한국과학기술연구원 | Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법 |
| DE102008001322A1 (de) | 2008-04-22 | 2009-10-29 | Linos Photonics Gmbh & Co. Kg | System zur optischen Analyse von Probenarrays |
| US8816095B2 (en) * | 2008-08-15 | 2014-08-26 | Georgetown University | Na channels, disease, and related assays and compositions |
| EP2654726A4 (en) | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd | SOLID DISPERSION FORMULATIONS AND METHODS OF USE |
| US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| KR101286424B1 (ko) * | 2011-04-27 | 2013-07-23 | 경상대학교산학협력단 | 양극성 장애 치료제의 스크리닝 방법 |
| CN104884632B (zh) | 2012-12-27 | 2018-01-02 | 索尼公司 | 细胞分析系统及细胞分析方法 |
| JP6942925B2 (ja) | 2013-11-08 | 2021-09-29 | ソニーグループ株式会社 | 細胞分析システム、細胞分析プログラム及び細胞分析方法 |
| CN116656770A (zh) * | 2023-04-21 | 2023-08-29 | 中国药科大学 | 一种细胞失水模型及其建立方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670113A (en) * | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
| US20020009772A1 (en) | 1997-02-28 | 2002-01-24 | Terry P. Snutch | Novel human calcium channels and related probes, cell lines and mehtods |
| US6309858B1 (en) | 1998-09-29 | 2001-10-30 | Syntex (U.S.A.) Llc | T-type calcium channel variants; compositions thereof; and uses |
| US6017537A (en) * | 1998-12-18 | 2000-01-25 | Connaught Laboratories, Inc. | Formyl methionyl peptide vaccine adjuvant |
| EP1180142A2 (en) * | 1999-05-27 | 2002-02-20 | PHARMACIA & UPJOHN COMPANY | Methods and compositions for measuring ion channel conductance |
| US6693172B1 (en) * | 1999-05-27 | 2004-02-17 | Pharmacia And Upjohn Company | Double mutant alpha-7 nicotinic acetylcholine receptor |
| EP1780278A3 (en) | 1999-07-02 | 2007-06-27 | Neuromed Technologies, Inc. | Mammalian calcium channels and related probes, cell lines and methods |
| US6358706B1 (en) | 1999-10-26 | 2002-03-19 | Ortho-Mcneil Pharmaceutical, Inc. | DNA encoding human alpha1G-C T-Type calcium channel |
| WO2001062741A1 (en) * | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Tetrahydronaphtalene derivatives and their use |
| US7399599B2 (en) * | 2000-07-10 | 2008-07-15 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
| GB0120589D0 (en) * | 2001-08-24 | 2001-10-17 | Glaxo Group Ltd | Assay |
| US20060014206A1 (en) * | 2002-10-10 | 2006-01-19 | Menghang Xia | Assay methods for state-dependent calcium channel agonists/antagonists |
-
2004
- 2004-01-07 US US10/754,085 patent/US7270949B2/en not_active Expired - Fee Related
- 2004-01-07 CA CA002512798A patent/CA2512798A1/en not_active Abandoned
- 2004-01-07 JP JP2006500430A patent/JP2006526389A/ja not_active Withdrawn
- 2004-01-07 WO PCT/CA2004/000023 patent/WO2004060917A2/en not_active Ceased
- 2004-01-07 EP EP04700421A patent/EP1581558A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004060917A2 (en) | 2004-07-22 |
| WO2004060917A3 (en) | 2004-12-16 |
| US20040180323A1 (en) | 2004-09-16 |
| EP1581558A2 (en) | 2005-10-05 |
| US7270949B2 (en) | 2007-09-18 |
| JP2006526389A (ja) | 2006-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matlashov et al. | Fluorescent ratiometric pH indicator SypHer2: applications in neuroscience and regenerative biology | |
| Khoshbouei et al. | Amphetamine-induced dopamine efflux: a voltage-sensitive and intracellular Na+-dependent mechanism | |
| Yu et al. | Detection of Calcium Transients in DrosophilaMushroom Body Neurons with Camgaroo Reporters | |
| Rackauskas et al. | Permeability of homotypic and heterotypic gap junction channels formed of cardiac connexins mCx30. 2, Cx40, Cx43, and Cx45 | |
| US7270949B2 (en) | Fluorescence based T-type channel assay | |
| Geibel et al. | The voltage-dependent proton pumping in bacteriorhodopsin is characterized by optoelectric behavior | |
| BRPI0618247A2 (pt) | ensaio de triagem de alto rendimento para canal iÈnico trpm5 | |
| Rossi et al. | Analysis of IP3 receptors in and out of cells | |
| Bedner et al. | A method to determine the relative cAMP permeability of connexin channels | |
| JP2011529564A (ja) | ナトリウム／カルシウム交換体（ｎｃｘ）「リバースモード」調節化合物を検出するための蛍光ベースのアッセイ | |
| Del Corsso et al. | Transfection of mammalian cells with connexins and measurement of voltage sensitivity of their gap junctions | |
| Betzenhauser et al. | Studying isoform-specific inositol 1, 4, 5-trisphosphate receptor function and regulation | |
| Kang et al. | Optical consequences of a genetically-encoded voltage indicator with a pH sensitive fluorescent protein | |
| JP5884222B2 (ja) | イオンチャネルに作用する化合物のスクリーニング用材料及びその利用 | |
| AU2008226101B2 (en) | Fluorescence-based assay for detecting compounds for modulating the sodium-calcium exchanger (NCX) in forward mode | |
| US20080039336A1 (en) | Methods of screening for trpm4 modulators of insulin secretion | |
| Chen et al. | Sweetness-induced activation of membrane dipole potential in STC-1 taste cells | |
| EP2108954A1 (en) | A test system for detecting intracellular cyclic nucleotide level and methods and uses thereof | |
| US20110117574A1 (en) | Fluorescence based assay to detect sodium/calcium exchanger "forward mode" modulating compounds | |
| JP2020529201A (ja) | 医薬品開発のための標的としてのオトペトリンプロトンチャネル | |
| Cheng | Biophysical studies of endocrine and synaptic release | |
| Sallinger | Characterisation and structural investigation of disease-related Orai1-T184 mutants/submitted by Matthias Sallinger BSc. | |
| Subthreshold | Combined Voltage and Calcium Epifluorescence | |
| HK1154074A (en) | Fluorescence based assay to detect sodium/calcium exchanger (ncx) "reverse mode" modulating compounds | |
| HK1154075A (en) | Fluorescence based assay to detect sodium/calcium exchanger "forward mode" modulating compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |